Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting (SIMPLE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01326598
Recruitment Status : Completed
First Posted : March 31, 2011
Last Update Posted : June 2, 2015
Integrated Medical Development
Information provided by (Responsible Party):
Valeritas, Inc.

Brief Summary:
The aim of the present study is to observe glycemic control, dose requirements, hypoglycemia risk, other possible adverse effects and weight changes, as well as to compare these parameters to prior treatment when patients with type 2 diabetes are initiated and treated using V-Go during circumstances as close to normal clinical practice as possible.

Condition or disease Intervention/treatment
Type 2 Diabetes Mellitus Device: V-Go™

Layout table for study information
Study Type : Observational
Actual Enrollment : 270 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting: A Long-term, Prospective, Observational Registry (SIMPLE)
Study Start Date : January 2012
Actual Primary Completion Date : March 2014
Actual Study Completion Date : May 2014

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
T2DM patients with A1C<7.0% Device: V-Go™
Use of Insulin Delivery Device, V-Go, and the effect on A1C for T2DM patients in five categories of baseline oral antidiabetes drug (OAD) use with or without insulin.

Primary Outcome Measures :
  1. The primary objective is to compare change of average glycemic control as measured by A1C from baseline to the end of V-Go use for the whole cohort as well as each of the five categories of baseline treatment. [ Time Frame: 12 month ]

Secondary Outcome Measures :
  1. Glycemic control is measured by the HbA1C from the beginning of the study to the end. [ Time Frame: 12 month ]
    To describe change of average glycemic control as measured by A1C from baseline to the particular time point of analysis irrespective of treatment, and to describe this change for subjects who are still treated with the V-Go and those who have switched to other therapies.

  2. To describe the incidence of hypoglycemia in participants as measured by blood glucose of <70 mg/dl. [ Time Frame: 12 month ]
    Occurrence of hypoglycemia confirmed with self monitored plasma referenced glucose measurement <70 mg/dl.

  3. Number of Participants with adverse events. [ Time Frame: 12 month ]
  4. How well the participants follow their doctors prescriptions for diabetes care. [ Time Frame: 12 month ]
    To describe frequency of self monitoring plasma glucose with V-Go therapy

  5. To describe insulin dose requirements from the beginning to the end of the study , and concomitant drugs to lower blood glucose. [ Time Frame: 12 month ]
    Some of the insulin dose requirement that will described are: starting dose, dose titration, basal rate selection, dose conversion from previous therapy.

  6. To describe changes in participants' weight from the beginning to the end of the study. [ Time Frame: 12 month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Type 2 Diabetes Mellitus

Inclusion Criteria:

  1. Diagnosed type 2 diabetes mellitus for at least 12 months.
  2. Must be and have been in stable treatment for at least a month within each of the following diabetes medication regimens:

    • OADs only,
    • OADs in combination with either exenatide, pramlintide, liraglutide (collectively termed "incretin mimetics") without receiving insulin,
    • Once or twice daily injection of an intermediate or long acting insulin (insulin NPH, insulin detemir or insulin glargine) with or without OADs and/or an incretin.
    • One to three daily injections of premix insulin (human insulin 70/30, insulin lispro 75/25 or insulin aspart 70/30) with or without OADs and/or an incretin.
    • Any insulin therapy with three or more insulin injections a day with or without OADs (MDI).
  3. Must be willing to self monitor glucose at least twice a day.
  4. The patient must be willing and able in the opinion of the investigator to try V-Go as therapy.
  5. Age between 21 and 80 years old, inclusive.
  6. A1C greater than or equal to 7.0%.

Exclusion Criteria:

  1. Acute infection with fever.
  2. Serum creatinine > 3.0 mg/dl if not on metformin, or if on metformin for females creatinine > 1.4 mg/dl, for males creatinine > 1.5 mg/dl within the last 6 months.
  3. Pregnancy, intention to become pregnant or failure to agree to use adequate contraceptive measures during the trial for females of current reproductive potential.Medically acceptable contraceptives include: (1) surgical sterilization (such as tubal ligation or hysterectomy), (2) approved hormonal contraceptives (pills, patches, implants, or injections), (3) barrier methods (condom, diaphragm) used with spermicide, or (4) intrauterine device (IUD). Contraceptive measures such as "Plan B™", for emergency use after unprotected sex, are not acceptable methods for routine use. A lifestyle of abstinence from sexual activity is an acceptable means of contraception. If currently abstinent, the subject must agree to use a double-barrier method as described above if they become sexually active during the study period.
  4. Any medical history of malignant melanoma or breast cancer.
  5. Medical history of any other cancers within the last five years except adequately treated basal cell carcinoma or cervical carcinoma in-situ.
  6. History of alcohol or drug abuse within the last year.
  7. Any medical condition that in the opinion of the investigator may preclude safe and successful completion of the trial.
  8. Participation in other clinical trials involving receipt of investigational drug that cannot be disclosed within the last 30 days.
  9. Unwillingness and/or inability to comply with study procedures.
  10. Require regular adjustments or modifications to the basal rate during a 24-hour period, or if the amount of insulin used at meals require adjustments of less-than 2-Unit increments.
  11. History of hypersensitivity or hyperreactivity to adhesives.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01326598

Show Show 25 study locations
Sponsors and Collaborators
Valeritas, Inc.
Integrated Medical Development
Layout table for investigator information
Principal Investigator: Nancy J. Bohannon, MD Nancy J. Bohannon Med. Corp
Principal Investigator: David Huffman, MD University Diabetes & Endocrine Consultants
Principal Investigator: George Grunberger, MD Grunberger Diabetes Institute
Principal Investigator: Kenneth Hershon, MD North Shore Diabetes & Endocrine Assoc.
Principal Investigator: Chip Reed, MD Endocrine Research Solutions, Inc.
Principal Investigator: Cheryl Rosenfeld, DO North Jersey Endocrine Consultants, LLCAND
Principal Investigator: Alan B. Schorr, DO Alan B. Schorr, DO FACE
Principal Investigator: Mark Warren, MD Physicians East, PA
Principal Investigator: Richard A. Guthrie, MD MidAmerica Diabetes Associates
Principal Investigator: Lenita Hanson, MD MEDSOL Clinical Research Center
Principal Investigator: Philip A. Levin, MD MODEL Clinical Research
Principal Investigator: Michael Shanik, MD Endocrine Associates of Long Island, PC
Principal Investigator: Kathryn Jean Lucas, MD Diabetes & Endocrinology Consultants
Principal Investigator: Mary Katherine Lawrence, MD Down East Medical Associates
Principal Investigator: Sherry Sussman, MD Middle Country Endocrinology, P.C.
Principal Investigator: Robert Bernstein, MD Regional Endocrinology Associates, PC
Principal Investigator: Albert Johary, MD Albert Johary M.D., P.C.
Principal Investigator: Jeffrey Rothman, MD University Physicians Group
Principal Investigator: Robert Savino, DO Western Connecticut Health Network, Inc.
Principal Investigator: Sarah Khan, MD Parsippany Endocrine, LLC
Principal Investigator: Jonathan Wilson, DO PMG Research of Winston-Salem
Principal Investigator: Stephanie Powell, MD PMG Research of Bristol
Principal Investigator: Rickey Manning, MD PMG Research of Knoxville
Principal Investigator: Georges M. Argoud, MD San Diego Coastal Endocrinology Group
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Valeritas, Inc. Identifier: NCT01326598    
Other Study ID Numbers: V4006
First Posted: March 31, 2011    Key Record Dates
Last Update Posted: June 2, 2015
Last Verified: June 2015
Keywords provided by Valeritas, Inc.:
V Go™
Type 2 Diabetes
Oral Anti Hypoglycemic Drugs
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases